#India #Gurgaon #Translumina #Drug-Coated Balloons #SPARX Study

Translumina Unveils SPARX: A Groundbreaking Global Trial

In an important advancement for cardiovascular medicine, Translumina Therapeutics has officially launched the global randomized controlled trial known as SPARX. This multinational study aims to assess the efficacy of drug-coated balloons (DCB) versus drug-eluting stents (DES) in patients suffering from complex coronary artery disease (CAD).

Study Overview

The SPARX trial seeks to generate comparative evidence regarding the safety, efficacy, and long-term outcomes of using DCBs as an initial treatment strategy. Unlike traditional stents, which can lead to late adverse events due to the presence of permanent metal implants, DCBs do not leave any permanent device behind. This offers a promising alternative treatment option, especially for patients where traditional methods have proven inadequate.

According to Professor Adnan Kastrati of the German Heart Center, who chairs the study, the trial is crucial in addressing a significant clinical need that has not been completely fulfilled. He points out that while drug-eluting stents are widely used, their associated risks highlight the urgent need for thorough investigations into alternative methods like DCBs in treating CAD. Kastrati asserts that the SPARX study is crucial for defining the future roles of DCBs within coronary interventions.

A Multinational Collaboration

The SPARX trial is a large-scale initiative, expecting to involve around 1,380 patients across ten countries. Each participant will be closely monitored over a two-year follow-up period with the primary outcome assessed at one year, focusing on device-oriented clinical endpoints (DOCE). This direct comparison is designed to provide robust, randomized data that can clarify the impact of DCB technology in clinical practice.

Co-lead investigator Professor Florim Cuculi from Luzerner Kantonsspital in Switzerland emphasizes the breadth of the trial's scope, asserting its role in advancing understanding of treatment strategies for a myriad of complex coronary lesions.

India's Key Role

The importance of India in this global trial cannot be overstated. Dr. Praveen Chandra, co-global lead investigator from Medanta, highlights that India has one of the highest worldwide coronary artery disease risks, which makes it an ideal setting for evaluating the effectiveness of DCBs. The study aims to produce clinically relevant evidence that can assist physicians in making informed therapeutic choices tailored to the complexities presented by the Indian patient population.

Sudipta Ghosh, CEO of Translumina's cardiovascular division, underscores the significance of SPARX, stating that it represents a vital step toward driving evidence-based innovation in interventional cardiology. Ghosh notes that the study is particularly focused on their proprietary Paclitaxel-coated balloon, Protégé™, which employs a unique drug delivery method designed to preserve drug integrity during the therapeutic process.

Through high-quality randomized clinical evidence, the SPARX trial aims to solidify the positioning of drug-coated balloons and the 'leave nothing behind' strategy for complex coronary artery disease, equipping physicians with the knowledge to deliver optimal patient care.

The global randomized controlled trial SPARX is backed by Translumina Therapeutics Private Limited, India.

• - CTRI Number: CTRI/2026/04/109375
• - ClinicalTrials.gov ID: NCT07397845

About Translumina

Founded as a significant subsidiary of Integris Medtech Limited, previously known as Integris Health Private Limited, Translumina operates as a leading company in cardiovascular medical technology. The organization is dedicated to advancing interventional cardiology through innovative solutions and clinical research grounded in solid evidence. It provides support to healthcare professionals across over 65 countries and maintains manufacturing facilities in India, Germany, and the Netherlands with internationally recognized quality certifications.

For more details, please visit integrismedtech.com.